Macrophage dysregulation in inflammatory bowel disease: cellular heterogeneity, pathogenic mechanism, and treatment - Takeaways - MDSpire

Macrophage dysregulation in inflammatory bowel disease: cellular heterogeneity, pathogenic mechanism, and treatment

  • By

  • Yuanyuan Yang

  • Haiying Zhu

  • May 21, 2026

  • 0 min

Share

  • 1

    Inflammatory bowel disease (IBD) involves dysregulated macrophages that shift from maintaining immune tolerance to amplifying inflammation.

  • 2

    Macrophage heterogeneity in IBD is characterized by distinct pathogenic states influenced by environmental factors and immune interactions.

  • 3

    Excessive monocyte recruitment in IBD leads to impaired differentiation into resident macrophages, promoting inflammatory responses.

  • 4

    Pathogenic macrophage phenotypes are shaped by genetic, transcriptional, and epitranscriptomic factors, contributing to IBD susceptibility.

  • 5

    Current therapeutic strategies targeting macrophages include nanomedicine and metabolic reprogramming, though challenges remain in their application.

Original Source(s)

Macrophage dysregulation in inflammatory bowel disease: cellular heterogeneity, pathogenic mechanism, and treatment

  • by Yuanyuan Yang, Haiying Zhu

  • May 21, 2026

Related Content

Ethosuximide vs Placebo for IBS Pain

Randomized trial found no improvement in abdominal pain and higher discontinuation rates with the calcium channel blocker.

The role of lipid metabolism and creeping fat in disease assessment and prediction for Crohn’s disease

Severity of surgical histopathological fibrosis predicted postoperative recurrence in Crohn’s disease: a multi-center retrospective cohort study